Moreover, patients presenting an EGFR promoter methylated tumour experienced in fact a worse clinical outcome thus confirming our hypothesis of a role for EGFR promoter methylation in determining the efficacy of anti-EGFR-targeted monoclonal antibodies. Here, EGFR is linked to neoplasm.